English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/212723
logo share SHARE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas)

AuthorsSanfilippo, Roberta; Jones, Robin L.; Blay, Jean-Yves; Cesne, Axel Le; Provenzano, Salvatore; Antoniou, Georgios; Mir, Olivier; Fucà, Giovanni; Fumagalli, Elena; Bertulli, Rossella; Stacchiotti, Silvia; Brahmi, Mehdi; Grosso, Federica; Dufresne, Armelle; Hindi, Nadia; Sbaraglia, Marta; Gronchi, Alesandro; Collini, Paola; Dei Tos, Angelo Paolo; Casali, Paolo G.
Issue Date2019
PublisherAmerican Association for Cancer Research
CitationClinical Cancer Research 25(17): 5295-5300 (2019)
Abstract[Purpose]: Perivascular epitheliod cell tumors (PEComas) are rare mesenchymal neoplasms for which the role of systemic treatments is not established as there are no published prospective clinical trials or sufficiently large retrospective case series. The aim of this study is to clarify the activity of conventional chemotherapy and biological agents in advanced/metastatic PEComas. [Experimental Design]: This was an observational, retrospective, international study that included patients with advanced/ metastatic PEComa treated with systemic therapy at 5 European sarcoma reference centers and within the Italian Rare Cancer Network. Survival analyses were performed using the Kaplan-Meier method and the Cox hazards regression models. [Results]: A total of 53 patients were included. Cytotoxic chemotherapy regimens were active only in a small proportion of PEComas. Gemcitabine-based regimens [objective response rate (ORR): 20%, median progression-free survival (PFS): 3.4 months] seemed to have the same activity of anthracycline- based regimens (ORR: 13%, median PFS: 3.2 months). Antiangiogenic agents resulted in disease stabilization in some patients, with a number having density changes/tissue response on imaging, with an ORR of 8.3% and a median PFS of 5.4 months. mTOR inhibitors were the most active agents, with an ORR of 41% and a median PFS of 9 months. [Conclusions]: Our study provides data for the selection of systemic therapy in patients with advanced/metastatic PEComa: mTOR inhibitors are the most active agents. Antiangiogenics and chemotherapy with gemcitabine-based regimens or anthracycline-based regimens are options in further line, but with a lower response rate and PFS.
Publisher version (URL)https://doi.org/10.1158/1078-0432.CCR-19-0288
Identifiersdoi: 10.1158/1078-0432.CCR-19-0288
e-issn: 1557-3265
issn: 1078-0432
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.